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Abstract 
Conjugate addition of 2-(bromomethyl)- and 2-(2-bromoethyl)piperidine hydrobromide to 
methyl and ethyl acrylate in the presence of triethylamine afforded the corresponding 3-[2-
(bromomethyl)piperidin-1-yl]propanoates and 3-[2-(2-bromoethyl)piperidin-1-yl]propanoates for 
the first time. Furthermore, methyl 3-[2-(bromomethyl)piperidin-1-yl]propanoate was converted 
into the novel 2-(methoxycarbonyl)indolizidine upon treatment with lithium diisopropylamide in 
THF. The latter ester was easily reduced by means of lithium aluminium hydride in diethyl ether, 
affording 2-(hydroxymethyl)indolizidine in high yield. 
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Introduction 
 
1The conjugate addition of amines onto α,β-unsaturated carbonyl compounds, often referred to 
as the ‘aza-Michael reaction’, comprises an important methodology in organic synthesis towards 
the preparation of β-aminocarbonyl derivatives.1 Furthermore, compounds containing the β-
aminocarbonyl motif in their molecular framework are of importance as biologically relevant 
targets and as intermediates in the synthesis of β-amino ketones, β-amino acids, and β-lactam 
antibiotics,2 hence the interest in their preparation. Whereas the 1,4-addition of a variety of 
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piperidine derivatives onto alkyl acrylates is known in the literature,3 the aza-Michael reaction of 
2-(ω-haloalkyl)piperidines has not been reported so far. 
In the present paper, the conjugate addition of 2-(bromomethyl)- and 2-(2-
bromoethyl)piperidines across methyl and ethyl acrylate is described. The applicability of the 
addition products is demonstrated by the synthesis of 2-(methoxycarbonyl)indolizidine for the 
first time, which was further reduced to 2-(hydroxymethyl)indolizidine. 
In the past decades, a whole range of lipophilic skin alkaloids has been isolated from frogs 
from the Dendrobatidae, Mantellinae, Myobatrachidae and Bufonidae families.4 Among others, 
pyrrolizidines, indolizidines and quinolizidines have been characterized. Besides from amphibian 
skin, interesting alkaloids were also isolated from plants5 and from micro-organisms.6 Many of 
these compounds have caught the attention of the medical world due to their potential biological 
activities,7 which explains the interest in new methodologies towards these azaheterocyles. 
 
 
Results and Discussion 
 
2-(Bromomethyl)- and 2-(2-bromoethyl)piperidine hydrobromide salts 2a,b were prepared from 
the corresponding alcohols 1a,b by treatment with hydrogen bromide in water (48%) upon reflux 
for 24 hours (Scheme 1), in accordance with a literature protocol.8 Despite their inherent 
reactivity and synthetic potential, β-bromoamines 2a and 2b have only been studied to a limited 
extend up to now.9 Subsequently, the conjugate addition of piperidines 2a,b onto alkyl acrylates 
was investigated. At first, 2-(bromomethyl)piperidine hydrobromide (2a) was treated with 1.05 
equiv of an acrylate (methyl, ethyl and tert-butyl acrylate) in dichloromethane in the presence of 
1.05 equiv of triethylamine at room temperature for 16 hours,3a albeit without any success. In all 
cases, no reaction was observed and the starting compound was recovered. If, however, 
piperidine hydrobromides 2a,b were suspended in methyl or ethyl acrylate, followed by the 
addition of 1.05 equiv of triethylamine at 0 °C, a stirring period of 16 hours at room temperature 
and then a second addition of 1.05 equiv of triethylamine, the corresponding novel 1-(2-
alkoxycarbonylethyl)piperidines 3a-d were isolated in good yields (Scheme 1). 
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It should be noted that the latter addition products 3 are rather unstable in pure form, and thus 
should be stored in solution (e.g. in diethyl ether) or used immediately for further elaboration. 
Furthermore, the presence of water has to be avoided during the aza-Michael addition, as 
nucleophilic displacement of bromide by water takes place smoothly and results in the formation 
of 2-(hydroxymethyl)- and 2-(2-hydroxyethyl)piperidines 4. The latter piperidine alcohols were 
also obtained as the major components upon attempted purification of 3-(piperidin-1-
yl)propanoates 3 by means of column chromatography on silica gel. Indeed, if water is added 
deliberately for the reaction of piperidines 2a,b with methyl acrylate (H2O/methyl acrylate 1/1) 
following the same procedure as described above (i.e. 2.1 equiv Et3N, 0 °C to r.t., 16 hours), 
methyl 3-[2-(hydroxymethyl)piperidin-1-yl]propanoate (4a) and methyl 3-[2-(2-
hydroxyethyl)piperidin-1-yl]propanoate (4b) were obtained as the sole reaction products in good 
yields (Scheme 2). 
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Scheme 2 
 
Based on detailed GC-analysis of the reaction mixtures obtained after treatment of piperidine 
hydrobromide 2a with acrylates in the presence of triethylamine, the presence of a minor 
constituent was observed in very small quantities (< 5%). This side-product could be isolated in 
pure form by means of preparative gas chromatography, and was identified as 4a,8a-
diazaperhydroanthracene (6).10 The formation of the latter tricyclic compound can be 
rationalized considering the dimerization of 2-(bromomethyl)piperidine (2a) through double 
nucleophilic substitution via intermediate 5 (Scheme 3). 
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In the final part, the application of 3-(piperidin-1-yl)propanoates 3 for the construction of a 
bicyclic framework was investigated. For this purpose, the reaction of methyl 3-[2-
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(bromomethyl)piperidin-1-yl]propanoate (3a) with lithium diisopropylamide (LDA) was 
evaluated with the intention to induce ring closure of the intermediate enolate 7, formed by α-
deprotonation by LDA, through nucleophilic displacement of bromide (Scheme 4). Thus, 
treatment of piperidine 3a with 1.1 equiv of LDA in THF at 0 °C afforded 2-
(methoxycarbonyl)indolizidine (8) for the first time after 16 hours at room temperature (Scheme 
4). Based on GC-analysis, two diastereomers cis-8 and trans-8 were present in the reaction 
mixture in a ratio of 45/55 (cis/trans or vice versa). These isomers appeared to be inseparable by 
means of column chromatography (SiO2) and preparative gas chromatography. Further 
derivatization of indolizidine ester 8 was performed using 2 equivalents of lithium aluminium 
hydride in diethyl ether, affording the corresponding 2-(hydroxymethyl)indolizidine (9)11 in high 
yield through reduction of the ester moiety (Scheme 4). Again, an inseparable mixture of two 
diastereomers (47/53 cis/trans or vice versa) was obtained. Extensive efforts towards the 
separation of the diastereomeric mixture of heterocycles 8 and 9 failed. 
The cyclization of 3-[2-(bromomethyl)piperidin-1-yl]propanoates towards the corresponding 
2-(alkoxycarbonyl)indolizidines via α-deprotonation constitutes a new synthetic methodology 
for the construction of the 1-azabicyclo[4.3.0]nonane skeleton. In the light of the broad 
biological importance of indolizidine alkaloids, the preparation of 2-
(methoxycarbonyl)indolizidine (8) and 2-(hydroxymethyl)indolizidine (9) might also be of 
relevance from a pharmaceutical point of view. 
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Scheme 4 
 
In summary, the ‘aza-Michael reaction’ of 2-(bromomethyl)- and 2-(2-bromoethyl)piperidine 
hydrobromide onto methyl and ethyl acrylate in the presence of triethylamine was described for 
the first time, affording the corresponding 3-[2-(bromomethyl)piperidin-1-yl]propanoates and 3-
[2-(2-bromoethyl)piperidin-1-yl]propanoates in good yields. Furthermore, methyl 3-[2-
(bromomethyl)piperidin-1-yl]propanoate was converted into the novel 2-
(methoxycarbonyl)indolizidine as a mixture of diastereomers upon treatment with lithium 
diisopropylamide in THF, representing a new synthetic approach towards the 1-
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azabicyclo[4.3.0]nonane skeleton. Finally, 2-(methoxycarbonyl)indolizidine was easily reduced 
by means of lithium aluminium hydride in diethyl ether, affording 2-
(hydroxymethyl)indolizidine in high yield. 
 
 
Experimental Section 
 
General Procedures. 1H NMR spectra were recorded at 270 MHz (JEOL JNM-EX 270) with 
CDCl3 as solvent and tetramethylsilane as internal standard. 13C NMR spectra were recorded at 
68 MHz (JEOL JNM-EX 270) with CDCl3 as solvent. Mass spectra were obtained with a mass 
spectrometer (VARIAN MAT 112, 70 eV) using a GC-MS coupling (RSL 200, 20 m glass 
capillary column, i.d. 0.53 mm, He carrier gas). IR spectra were measured with a Perkin Elmer 
1310 spectrophotometer or a Spectrum One FT-IR. Elemental analyses were performed with a 
PerkinElmer Series II CHNS/O Analyzer 2400. Dichloromethane was dried over calcium 
hydride, while diethyl ether and THF were dried by distillation over sodium benzophenone ketyl. 
Other solvents were used as received from the supplier. 
 
Synthesis of 3-[2-(bromomethyl)piperidin-1-yl]propanoates 3a,b and 3-[2-(2-
bromoethyl)piperidin-1-yl]propanoates 3c,d. General procedure 
To an ice-cooled suspension of dry piperidine hydrobromide 2 (5 mmol) in alkyl acrylate (5 mL) 
was added slowly triethylamine (5.25 mmol). The resulting mixture was stirred for 16 hours at 
room temperature, after which an additional amount of triethylamine (5.25 mmol) was added. 
After 10 minutes, the excess of alkyl acrylate and triethylamine was removed in vacuo, and the 
obtained paste was suspended in diethyl ether (10 mL). After a stirring period of 10 minutes at 
room temperature, the resulting mixture was filtered under nitrogen atmosphere and the solvent 
was removed in vacuo, affording alkyl 3-(piperidin-1-yl)propanoate 3. Due to its lability, the 
crude alkyl 3-(piperidin-1-yl)propanoate 3 was used immediately as such for further elaboration 
or dissolved in dry diethyl ether for conservation at -18 °C. Because of the instability of 
propanoates 3, no elemental analyses were performed. 
Methyl 3-[2-(bromomethyl)piperidin-1-yl]propanoate (3a). 1H NMR (270 MHz, CDCl3): δ 
1.25-1.74 (6H, m); 2.24-2.37 (1H, m); 2.45-2.60 (3H, m); 2.75-2.88 (2H, m); 2.94-3.07 (1H, m); 
3.45-3.55 (2H, m); 3.68 (3H, s). 13C NMR (68 MHz, CDCl3): δ 22.5, 25.3, 29.6, 31.3, 34.8, 49.1, 
50.9, 51.5, 59.8, 172.8. IR (NaCl): ν = 1730 cm-1 (C=O). MS (70 eV): m/z (%): 263/5 (1, M+), 
190/2 (14); 184 (12); 170 (100); 110 (15); 96 (61); 59 (10); 56 (10); 55 (26). 
Ethyl 3-[2-(bromomethyl)piperidin-1-yl]propanoate (3b). 1H NMR (270 MHz, CDCl3): δ 
1.26 (3H, t, J = 7.2 Hz); 1.25-1.76 (6H, m); 2.26-2.38 (1H, m); 2.43-2.60 (3H, m); 2.75-2.89 
(2H, m); 2.93-3.07 (1H, m); 3.45-3.58 (2H, m); 4.14 (2H, q, J = 7.2 Hz). 13C NMR (68 MHz, 
CDCl3): δ 13.8, 22.1, 24.9, 29.2, 30.9, 34.4, 48.7, 50.4, 59.2, 59.9, 172.1. IR (NaCl): ν = 1729 
cm-1 (C=O). MS (70 eV): m/z (%): no M+; 198 (23); 190/2 (13); 184 (100); 110 (62); 84 (18); 55 
(23). 
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Methyl 3-[2-(2-bromoethyl)piperidin-1-yl]propanoate (3c). 1H NMR (270 MHz, CDCl3): δ 
1.24-1.78 (6H, m); 1.88-2.05 (1H, m); 2.09-2.24 (1H, m); 2.26-2.36 (1H, m); 2.43-2.57 (3H, m); 
2.68-2.87 (2H, m); 2.92-3.04 (1H, m); 3.33-3.57 (2H, m); 3.71 (3H, s). 13C NMR (68 MHz, 
CDCl3): δ 22.5, 22.8, 28.9, 30.7, 31.8, 34.3, 48.6, 50.5, 51.5, 58.1, 173.1. IR (NaCl): ν = 1736 
cm-1 (C=O). MS (70 eV): m/z (%): 277/9 (1, M+); 204 (10); 171 (10); 170 (100); 92 (28); 55 
(17). 
Ethyl 3-[2-(2-bromoethyl)piperidin-1-yl]propanoate (3d). 1H NMR (270 MHz, CDCl3): δ 
1.27 (3H, t, J = 6.8 Hz); 1.23-1.77 (6H, m); 1.88-2.03 (1H, m); 2.09-2.22 (1H, m); 2.23-2.35 
(1H, m); 2.42-2.57 (3H, m); 2.68-2.88 (2H, m); 2.91-3.04 (1H, m); 3.33-3.57 (2H, m); 4.13 (2H, 
q, J = 6.8 Hz). 13C NMR (68 MHz, CDCl3): δ 13.8, 22.4, 24.1, 28.6, 30.3, 31.6, 33.9, 48.2, 50.2, 
57.7, 59.9, 172.3. IR (NaCl): ν = 1734 cm-1 (C=O). MS (70 eV): m/z (%): 292/4 (100, M++H). 
 
Synthesis of 3-[2-(hydroxymethyl)piperidin-1-yl]propanoate (4a) and 3-[2-(2-
hydroxyethyl)piperidin-1-yl]propanoate (4b). General procedure 
To an ice-cooled suspension of piperidine hydrobromide 2 (5 mmol) in methyl acrylate (5 mL) 
and water (5 mL) was added slowly triethylamine (5.25 mmol). The resulting mixture was stirred 
for 16 hours at room temperature, after which an additional amount of triethylamine (5.25 mmol) 
was added. After 10 minutes, the excess of methyl acrylate and triethylamine was removed in 
vacuo, and the obtained paste was suspended in diethyl ether (10 mL). After a stirring period of 
10 minutes at room temperature, the resulting mixture was filtered under nitrogen atmosphere 
and the solvent was removed in vacuo, affording methyl 3-(piperidin-1-yl)propanoate 4. 
Methyl 3-[2-(hydroxymethyl)piperidin-1-yl]propanoate (4a). 1H NMR (270 MHz, CDCl3): δ 
1.20-1.76 (6H, m); 2.12-2.24 (1H, m); 2.26-2.38 (1H, m); 2.39-2.63 (3H, m); 2.75-3.27 (3H, m); 
3.43 (1H, d×d, J = 11.5, 3.9 Hz); 3.69 (3H, s); 3.83 (1H, d×d, J = 11.5, 3.9 Hz). 13C NMR (68 
MHz, CDCl3): δ 23.0, 25.3, 29.6, 30.8, 47.6, 50.9, 51.1, 60.9, 62.1, 172.9. IR (NaCl): ν = 3640-
3080 cm-1 (OH), 1725 cm-1 (C=O). MS (70 eV): m/z (%): 202 (100, M++H). Purity (NMR) > 
95%. Anal. Calcd for C10H19NO3: C 59.68, H 9.52, N 6.96. Found: C 59.81, H 9.77, N 6.85. 
Methyl 3-[2-(2-hydroxyethyl)piperidin-1-yl]propanoate (4b). 1H NMR (270 MHz, CDCl3): δ 
1.18-1.76 (6H, m); 1.78-1.94 (1H, m); 2.02-2.17 (1H, m); 2.22-2.37 (1H, m); 2.41-2.60 (3H, m); 
2.69-2.89 (2H, m); 2.92-3.05 (1H, m); 3.48-3.65 (1H, m); 3.68 (3H, s); 3.74-3.85 (1H, m); 5.31 
(1H, s). 13C NMR (68 MHz, CDCl3): δ 22.9, 24.6, 29.2, 31.7, 34.1, 48.6, 50.8, 51.6, 57.1, 60.8, 
173.2. IR (NaCl): ν = 3425 cm-1 (OH), 1732 cm-1 (C=O). MS (70 eV): m/z (%): no M+; 171 (9); 
170 (100); 97 (10); 96 (33); 86 (10); 84 (28); 55 (13). Purity (NMR) > 95%. Anal. Calcd for 
C11H21NO3: C 61.37, H 9.83, N 6.51. Found: C 61.47, H 10.02, N 6.66. 
Synthesis of 2-(methoxycarbonyl)indolizidine (8). To an ice-cooled solution of 
diisopropylamine (5.5 mmol) in dry tetrahydrofuran (10 mL) under nitrogen atmosphere was 
added slowly n-butyllithium (2.2 mL, 2.5 M in hexane) via a syringe. After 10 minutes, a 
solution of methyl 3-[2-(bromomethyl)piperidin-1-yl]propanoate (3a) (5 mmol) in THF (4 mL) 
was added, after which the resulting mixture was stirred for 16 hours at room temperature. 
Afterwards, the reaction mixture was poured into water (20 mL) and extracted with diethyl ether 
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(3 × 15 mL). Drying (MgSO4), filtration of the drying agent and removal of the solvent in vacuo 
afforded 2-(methoxycarbonyl)indolizidine (8) in 73% yield as a mixture of diastereomers in a 
45/55 ratio. 1H NMR (270 MHz, CDCl3): δ 1.13-2.19, 2.26-2.38, 2.45-2.59, 2.75-2.90 and 2.98-
3.12 (2×14H, 5×m); 3.68 (2×3H, s). 13C NMR (68 MHz, CDCl3): δ 24.2, 25.1, 25.3, 30.5, 30.8, 
34.4, 34.7, 39.6, 51.7, 51.8, 52.7, 52.7, 56.7, 57.7, 63.6, 64.4, 175.6, 175.7. IR (NaCl): ν = 1740 
cm-1 (C=O). MS (70 eV): m/z (%): 183 (48, M+); 182 (81); 168 (97); 154 (28); 152 (39); 124 
(66); 123 (10); 122 (28); 97 (100); 96 (55); 94 (20); 83 (29); 82 (23); 81 (14); 80 (17); 69 (44); 
68 (51); 67 (14); 56 (11); 55 (39); 54 (15); 53 (12). Purity (NMR) > 95%. Anal. Calcd for 
C11H21NO3: C 65.54, H 9.35, N 7.64. Found: C 65.37, H 9.63, N 7.49. 
Synthesis of 2-(hydroxymethyl)indolizidine (9). To an ice-cooled solution of 2-
(methoxycarbonyl)indolizidine (8) (2 mmol) in dry diethyl ether (5 mL) was added slowly 
LiAlH4 (4 mmol). After heating 3 hours under reflux, water (0.5 mL) was added at 0 °C in order 
to neutralize the excess of LiAlH4. The mixture was stirred for 10 minutes, after which the grey 
suspension was filtered over K2CO3 and celite. The filter cake was then washed thoroughly with 
dry ether (3 × 5 mL). After removal of the solvent in vacuo, 2-(hydroxymethyl)indolizidine (9)11 
was obtained in 92% yield as a mixture of diastereomers in a 47/53 ratio. 1H NMR (270 MHz, 
CDCl3): δ 1.15-2.13, 2.18-2.54 and 2.61-3.15 (2×14H, 3×m); 3.35-3.75 (2×2H, m). 13C NMR (68 
MHz, CDCl3): δ 24.4, 25.3, 25.4, 25.5, 30.8, 30.9, 34.4, 34.5, 36.8, 37.4, 52.9, 53.1, 58.1, 58.5, 
63.4, 64.6, 65.5, 67.0. IR (NaCl): ν = 3380 cm-1 (OH). 
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